Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Dexcom (DXCM) Return on Invested Capital (2016 - 2025)

Dexcom (DXCM) has disclosed Return on Invested Capital for 11 consecutive years, with 0.26% as the latest value for Q4 2025.

  • On a quarterly basis, Return on Invested Capital rose 2.0% to 0.26% in Q4 2025 year-over-year; TTM through Dec 2025 was 0.26%, a 2.0% increase, with the full-year FY2025 number at 0.29%, up 6.0% from a year prior.
  • Return on Invested Capital was 0.26% for Q4 2025 at Dexcom, up from 0.22% in the prior quarter.
  • In the past five years, Return on Invested Capital ranged from a high of 0.36% in Q1 2021 to a low of 0.11% in Q2 2022.
  • A 5-year average of 0.21% and a median of 0.21% in 2023 define the central range for Return on Invested Capital.
  • Biggest YoY gain for Return on Invested Capital was 16bps in 2021; the steepest drop was -25bps in 2021.
  • Dexcom's Return on Invested Capital stood at 0.11% in 2021, then surged by 52bps to 0.17% in 2022, then increased by 22bps to 0.21% in 2023, then rose by 14bps to 0.24% in 2024, then rose by 7bps to 0.26% in 2025.
  • Per Business Quant, the three most recent readings for DXCM's Return on Invested Capital are 0.26% (Q4 2025), 0.22% (Q3 2025), and 0.21% (Q2 2025).